All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-02-18T14:55:42.000Z

JULIET: What factors predict response to tisa-cel?

By Georgia Scurfield, Amalia Zachariadis, Sumayya Khan, Joshua Reid
Featured
Ulrich Jäger
Feb 18, 2021
Share:

Bookmark this article

During the 2021 TCT Meetings Digital Experience, the Lymphoma Hub spoke to Ulrich Jäger, Medical University of Vienna, Vienna, AT. We asked, What factors predict response to tisa-cel?

JULIET: What factors predict response to tisa-cel?

Jäger overviews a histopathologic analysis of the JULIET trial, which observed outcomes in patients with DLBCL receiving tisagenlecleucel (tisa-cel). He outlines the correlation of biological factors, including Myc expression, tumor infiltrating CD3 cells, and the quantity of LAG3 CD3+ T cells, with patient outcomes.

More about...
Aggressive B-cell lymphomasDiffuse large B-cell lymphomaJULIETTCT 2021Tisagenlecleucel

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

EHA 2019 | How will the sequencing of treatments for DLBCL change in the future?

Ulrich Jäger from the Medical University of Vienna, Vienna, AT, discusses how to decide what treatments to use, and when, for patients with relapsed/refractory (R/R)...

Jun 20, 2019
Add bookmark

EHA 2019 | How will the sequencing of treatments for DLBCL change in the future?

Ulrich Jäger from the Medical University of Vienna, Vienna, AT, discusses how to decide what treatments to use, and...

Jun 20, 2019
Add bookmark

EBMT Debate Session | How to treat R/R DLBCL in 2019? | Part 2 – Allo-SCT

A Keynote Debate Session on how to treat patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) took place on Tuesday 26 March 2019, during the 45th...

Apr 4, 2019
Add bookmark

EBMT Debate Session | How to treat R/R DLBCL in 2019? | Part 2 – Allo-SCT

A Keynote Debate Session on how to treat patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) took...

Apr 4, 2019

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox